Literature DB >> 6428913

Long-term effects of captopril on renal function in hypertensive patients.

Z Glück, C Beretta-Piccoli, F C Reubi.   

Abstract

The effect of captopril up to 450 mg/day on blood pressure and renal function were investigated during sustained treatment of 10 patients whose severe hypertension had not responded to previous therapy. All the patients were kept on diuretics and most of them on beta-blockers, too. A control determination of glomerular filtration rate (GFR) and para-aminohippuric acid clearance (CPAH) was performed during the prior treatment. The effect of the addition (or substitution) of captopril were assessed after an average of 25 days (short-term) and 26 weeks (long-term). Short-term treatment produced a 15.5% decrease in mean blood pressure and interindividually variable effects on renal function. On average GFR was somewhat lower and CPAH slightly higher than the control values (not significant). This pattern is quite similar to the effects of most other antihypertensive drugs. On long-term therapy GFR rose by a mean of 9% (NS) and CPAH by 17% (p less than 0.02). However, in a patient who developed a captopril-induced nephrotic syndrome, GFR dropped to 56% and CPAH to 50% of the control values. In another patient a transient rise in serum creatinine accompanied a severe drug reaction.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6428913     DOI: 10.1007/bf00548761

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  24 in total

1.  Inhibition of angiotensin-converting enzyme by SQ 14,225 in anesthetized dogs: hemodynamic and renal vascular effects.

Authors:  V S Murthy; T L Waldron; M E Goldberg
Journal:  Proc Soc Exp Biol Med       Date:  1978-01

2.  Treatment of essential hypertension with a new vasodilator in combination with beta-adrenergic blockade.

Authors:  E Gilmore; J Weil; C Chidsey
Journal:  N Engl J Med       Date:  1970-03-05       Impact factor: 91.245

3.  Clonidine: a new antihypertensive agent.

Authors:  G Onesti; K D Bock; V Heimsoth; K E Kim; P Merguet
Journal:  Am J Cardiol       Date:  1971-07       Impact factor: 2.778

4.  Immune-complex glomerulopathy in patients treated with captopril.

Authors:  S J Hoorntje; C G Kallenberg; J J Weening; A J Donker; T H The; P J Hoedemaeker
Journal:  Lancet       Date:  1980-06-07       Impact factor: 79.321

Review 5.  Effects of captopril in animal models of hypertension.

Authors:  M J Antonaccio; B Rubin; Z P Horovitz
Journal:  Clin Exp Hypertens       Date:  1980       Impact factor: 1.749

6.  Hemodynamic and volume changes associated with captopril.

Authors:  R C Tarazi; E L Bravo; F M Fouad; P Omvik; R J Cody
Journal:  Hypertension       Date:  1980 Jul-Aug       Impact factor: 10.190

7.  Sodium intake and renal responses to captopril in normal man and in essential hypertension.

Authors:  N K Hollenberg; L G Meggs; G H Williams; J Katz; J D Garnic; D P Harrington
Journal:  Kidney Int       Date:  1981-08       Impact factor: 10.612

8.  [Comparative studies on the renal clearance of Na-Cr2Cr51 ethylenediaminetetraacetate, inulin and sodium thiosulfate in humans].

Authors:  C Vorburger; H Riedwyl; F Reubi
Journal:  Klin Wochenschr       Date:  1969-04-15

9.  Effect of captopril on renal vascular tone in patients with essential hypertension.

Authors:  A Mimran; H R Brunner; G A Turini; B Waeber; D Brunner
Journal:  Clin Sci (Lond)       Date:  1979-12       Impact factor: 6.124

10.  Dependence of renal vasodilator effect of captopril on prevailing plasma renin level in the dog: influence of DOCA-salt treatment.

Authors:  P C Wong; B G Zimmerman
Journal:  Clin Sci (Lond)       Date:  1982-10       Impact factor: 6.124

View more
  5 in total

Review 1.  Safety profiles of the angiotensin-converting enzyme inhibitors.

Authors:  N J Warner; J E Rush
Journal:  Drugs       Date:  1988       Impact factor: 9.546

Review 2.  Captopril. An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure.

Authors:  R N Brogden; P A Todd; E M Sorkin
Journal:  Drugs       Date:  1988-11       Impact factor: 9.546

3.  [Results of a 5-year study with captopril in patients with severe therapy-resistant hypertension].

Authors:  J Schrader; G Schoel; F Scheler
Journal:  Klin Wochenschr       Date:  1986-08-01

4.  Effect of captopril on renal haemodynamics and the renin-angiotensin-aldosterone and osmoregulatory systems in essential hypertension.

Authors:  O O Thomsen; H Danielsen; S S Sørensen; E B Pedersen
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

5.  Potential drug-drug interactions in the medication of medical patients at hospital discharge.

Authors:  Sabin S Egger; Jürgen Drewe; Raymond G Schlienger
Journal:  Eur J Clin Pharmacol       Date:  2003-02-21       Impact factor: 2.953

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.